Arkolith/Insider Trading/EIGR/Form 4

Dietz Thomas John

DirectorEiger BioPharmaceuticals, Inc. (EIGR) · full profile →Form 4 · filed Dec 27, 2022
Net Selling
Open-Market Buys
$0
Open-Market Sells
$26K
Net Open-Market Flow
-$26K
Transactions
1
1 non-derivative · 0 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Dec 22, 2022Sell(S)23K$1.17$26K21K

Transaction Codes

S
Open-market sale

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001140361-22-047071) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML